|
Bluebird Bio, Inc. (azul) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
bluebird bio, Inc. (BLUE) Bundle
¡Simplifique Bluebird Bio, Inc. (azul) Valoración con esta calculadora DCF personalizable! Con Real Bluebird Bio, Inc. (azul) financieras y entradas de pronóstico ajustables, puede probar escenarios y descubrir el valor razonable de Bluebird Bio, Inc. (azul) en minutos.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.7 | 250.7 | 3.7 | 3.6 | 29.5 | 36.8 | 46.0 | 57.5 | 71.8 | 89.7 |
| Revenue Growth, % | 0 | 461.25 | -98.54 | -1.77 | 720.04 | 24.92 | 24.92 | 24.92 | 24.92 | 24.92 |
| EBITDA | -772.7 | -553.6 | -556.9 | -215.6 | -167.2 | -36.8 | -46.0 | -57.5 | -71.8 | -89.7 |
| EBITDA, % | -1729.68 | -220.8 | -15208.25 | -5992.74 | -566.71 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 17.4 | 5.6 | 5.5 | 5.0 | 28.5 | 24.9 | 31.1 | 38.9 | 48.6 | 60.7 |
| Depreciation, % | 39.02 | 2.24 | 148.94 | 139.03 | 96.7 | 67.59 | 67.59 | 67.59 | 67.59 | 67.59 |
| EBIT | -790.2 | -559.3 | -562.4 | -220.6 | -195.7 | -36.8 | -46.0 | -57.5 | -71.8 | -89.7 |
| EBIT, % | -1768.71 | -223.05 | -15357.18 | -6131.78 | -663.41 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 1,238.0 | 1,274.1 | 396.6 | 181.7 | 221.8 | 36.8 | 46.0 | 57.5 | 71.8 | 89.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 12.8 | 2.4 | 11.4 | 10.8 | 13.0 | 20.2 | 25.2 | 31.5 | 39.3 | 49.1 |
| Account Receivables, % | 28.71 | 0.94602 | 311 | 299.89 | 44.1 | 54.75 | 54.75 | 54.75 | 54.75 | 54.75 |
| Inventories | -144.3 | -149.7 | -108.5 | -1.4 | 22.9 | -16.3 | -20.4 | -25.5 | -31.8 | -39.7 |
| Inventories, % | -323.08 | -59.71 | -2962.94 | -39.31 | 77.7 | -44.26 | -44.26 | -44.26 | -44.26 | -44.26 |
| Accounts Payable | 43.0 | 13.8 | 25.9 | 14.9 | 18.5 | 26.9 | 33.6 | 41.9 | 52.4 | 65.4 |
| Accounts Payable, % | 96.24 | 5.51 | 706.8 | 413.32 | 62.71 | 72.89 | 72.89 | 72.89 | 72.89 | 72.89 |
| Capital Expenditure | -76.3 | -29.0 | -23.0 | -13.2 | -9.1 | -25.2 | -31.5 | -39.4 | -49.2 | -61.4 |
| Capital Expenditure, % | -170.69 | -11.56 | -628.15 | -367.19 | -30.7 | -68.45 | -68.45 | -68.45 | -68.45 | -68.45 |
| Tax Rate, % | 0.05942303 | 0.05942303 | 0.05942303 | 0.05942303 | 0.05942303 | 0.05942303 | 0.05942303 | 0.05942303 | 0.05942303 | 0.05942303 |
| EBITAT | -789.6 | -559.9 | -562.6 | -220.7 | -195.6 | -36.8 | -46.0 | -57.5 | -71.8 | -89.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -673.9 | -596.6 | -618.3 | -346.4 | -199.0 | 3.3 | -40.7 | -50.8 | -63.5 | -79.3 |
| WACC, % | 7.4 | 7.4 | 7.4 | 7.4 | 7.4 | 7.4 | 7.4 | 7.4 | 7.4 | 7.4 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -176.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -81 | |||||||||
| Terminal Value | -1,498 | |||||||||
| Present Terminal Value | -1,048 | |||||||||
| Enterprise Value | -1,225 | |||||||||
| Net Debt | 109 | |||||||||
| Equity Value | -1,333 | |||||||||
| Diluted Shares Outstanding, MM | 110 | |||||||||
| Equity Value Per Share | -12.14 |
What You Will Get
- Real bluebird bio Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on bluebird bio’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Customizable Clinical Parameters: Adjust essential inputs such as treatment efficacy, patient demographics, and cost projections.
- Instant DCF Valuation: Computes intrinsic value, net present value, and other financial metrics on-the-fly.
- High-Precision Accuracy: Leverages bluebird bio’s actual financial data for credible valuation results.
- Effortless Scenario Analysis: Explore various assumptions and assess different outcomes with ease.
- Efficiency Booster: Remove the hassle of constructing intricate valuation models from the ground up.
How It Works
- Download the Template: Gain immediate access to the Excel-based BLUE DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and more.
- Instant Calculations: The model automatically recalculates bluebird bio, Inc.’s intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the results to inform your investment or financial analysis.
Why Choose bluebird bio, Inc. (BLUE)?
- Innovative Solutions: Pioneering gene therapies that address serious genetic diseases.
- Proven Expertise: Backed by a team of leading scientists and industry professionals.
- Patient-Centric Approach: Focused on improving patient outcomes and quality of life.
- Robust Pipeline: A diverse range of therapies in various stages of development.
- Strong Community Impact: Committed to engaging with patients and advocacy groups.
Who Should Use This Product?
- Biotech Students: Explore gene therapy techniques and apply them with real-world data.
- Researchers: Integrate advanced models into your studies or clinical research.
- Investors: Validate your investment strategies and evaluate valuation metrics for bluebird bio, Inc. (BLUE).
- Market Analysts: Enhance your analysis with a customizable financial model tailored for biotech companies.
- Healthcare Entrepreneurs: Understand how leading biotech firms like bluebird bio, Inc. (BLUE) are assessed in the market.
What the Template Contains
- Preloaded BLUE Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.